Advertisement
A vs CLPT
Which Stock Would AI Choose? Agilent Technologies (A) vs. ClearPoint Neuro (CLPT) Stock Comparison
Key Takeaways
- Agilent Technologies (A) is a large-cap life sciences and diagnostics leader with strong profitability and accelerating revenue growth.
- ClearPoint Neuro (CLPT) is a small-cap medical device company growing quickly but still operating at a loss.
- The two stocks occupy different ends of the healthcare spectrum: a diversified instruments giant versus a niche neurosurgical platform.
- A offers stability, margin expansion, and a dividend, while CLPT carries higher growth potential and higher volatility.
- Recent momentum favors A, which has beaten earnings expectations, while CLPT has lagged the broader market this year.
Introduction
Investors evaluating healthcare and life sciences names often weigh the trade-off between established, cash-generating franchises and earlier-stage innovators with outsized growth optionality. This stock comparison puts those two profiles side by side. Agilent Technologies (A) is a diversified analytical instruments and diagnostics company serving pharmaceutical, chemical, and clinical markets, while ClearPoint Neuro (CLPT) is a focused developer of neurosurgical navigation and drug delivery technologies. Their differing market positioning, growth drivers, and risk profiles make this comparison relevant to growth investors, long-term holders, and traders tracking relative performance across the healthcare sector.
A Overview and Recent Performance
Agilent Technologies (A) provides laboratory instruments, consumables, and software across life sciences, diagnostics, and applied markets. With a market capitalization above $40 billion, it is among the larger analytical instrument providers globally. In recent quarters, the company has delivered accelerating results, reporting third-quarter fiscal 2026 revenue of roughly $1.88 billion with core revenue growth of about 7.3%, exceeding the high end of its guidance. Earnings per share (EPS) rose roughly 14% year over year, and operating margin expanded materially, reflecting the company's "Ignite" operating system initiatives around pricing, procurement, and supply-chain efficiency.
Growth has been broad-based, led by pharmaceutical demand, a rebound in China, and strength in advanced materials tied to semiconductor-related customers. Recent market activity has also reflected upbeat analyst sentiment, including multiple upgrades and favorable price-target revisions. The company raised its full-year revenue and EPS guidance, and management has highlighted a book-to-bill ratio (orders relative to billed revenue) above one for ten consecutive quarters, a sign of sustained demand. These factors have contributed to relatively consistent, positive momentum and a lower-volatility profile than many smaller healthcare peers.
CLPT Overview and Recent Performance
ClearPoint Neuro (CLPT) develops minimally invasive neurosurgical navigation, drug delivery, and cranial access technologies, with a growing focus on enabling cell and gene therapies delivered to the brain. As a much smaller company, its market capitalization and revenue base are a fraction of Agilent's. In its most recent reported quarter, ClearPoint generated record revenue of about $12.1 million, up 43% year over year, driven in part by the integration of the IRRAflow product line acquired in late 2025. Organic device growth was roughly 25%, and gross margin improved to about 64%.
Despite rapid top-line growth, the company remains unprofitable, posting an operating loss as it invests in research, sales infrastructure, and a new laboratory facility. ClearPoint has also seen volatility tied to regulatory developments among its biopharma partners, as its outlook is partly dependent on the timing of partners' clinical trials and approvals. In recent weeks, sentiment has been mixed, with shares underperforming the broader market so far this year, reflecting both the company's growth potential and its elevated execution and cash-burn risks.
Trending AI Robots
For traders seeking a data-driven edge across names like A and CLPT, Tickeron offers a broad library of AI Trading Bots that collectively trade thousands of different tickers. Because not every bot fits every market regime, Tickeron curates its Trending AI Robots section to spotlight only the strategies best suited to current conditions. These bots vary widely in trading style, timeframe, risk profile, and the baskets of tickers they monitor, with hundreds of automated strategies available across different performance and statistical benchmarks. Reviewing the curated selection can help investors identify approaches that align with their own objectives and risk tolerance.
Head-to-Head Comparison
The clearest contrast between these two companies is scale and maturity. A is a profitable, diversified enterprise with recurring revenue representing a large share of sales, giving it steadier cash flows and a dividend. CLPT is a growth-stage, single-platform business whose financials remain loss-making and more sensitive to a smaller set of catalysts, notably partner therapy approvals.
Growth drivers also differ sharply. Agilent benefits from instrument replacement cycles, pharmaceutical reshoring, GLP-1-related demand, and semiconductor materials strength. ClearPoint's trajectory is tied to the adoption of gene and cell therapies, new product launches, and international expansion. Sector exposure is another differentiator: Agilent spans multiple end markets across life sciences and diagnostics, while ClearPoint is concentrated in neurosurgery and central nervous system drug delivery.
On risk, A carries comparatively lower operational risk but remains exposed to macro spending cycles and tariffs. CLPT faces higher binary risk from regulatory outcomes and its ongoing cash burn, alongside the potential for sharp price moves in either direction. In terms of recent momentum, Agilent has posted consistent earnings beats and guidance raises, whereas ClearPoint has experienced choppier market positioning.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and catalyst quality, Tickeron's AI would likely favor Agilent Technologies (A) in the current environment. The stock's sustained book-to-bill strength, expanding margins, analyst upgrades, and raised guidance point to a more durable and lower-volatility trend than ClearPoint's earlier-stage, catalyst-dependent profile. That said, ClearPoint Neuro (CLPT) offers meaningfully higher growth optionality that could reward investors comfortable with elevated risk. The balance of current evidence suggests Agilent presents the more stable relative positioning, while ClearPoint may appeal to those prioritizing long-term growth potential over near-term predictability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Buy and CLPT is a StrongBuy.
Aroon Indicator for A shows an upward move is likely
A's Aroon Indicator triggered a bullish signal on October 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 209 similar instances where the Aroon Indicator showed a similar pattern. In 141 of the 209 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on A as a result. In 58 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
Following a +4.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 188 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 23 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 29 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.806) is normal, around the industry mean (64.450). P/E Ratio (34.921) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
CLPT in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 29, 2026
CLPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where CLPT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLPT's RSI Indicator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 216 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for CLPT turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 47 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
CLPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CLPT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (26.184) is slightly higher than the industry average of (2.923). P/E Ratio (-7.839) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
A | CLPT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 88 | 100 | |
SMR RATING 1..100 | 45 | 100 | |
PRICE GROWTH RATING 1..100 | 6 | 86 | |
P/E GROWTH RATING 1..100 | 37 | 14 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (24) in the Biotechnology industry is in the same range as CLPT (31) in the null industry. This means that A’s stock grew similarly to CLPT’s over the last 12 months.
A's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as CLPT (100) in the null industry. This means that A’s stock grew similarly to CLPT’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for CLPT (100) in the null industry. This means that A’s stock grew somewhat faster than CLPT’s over the last 12 months.
A's Price Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for CLPT (86) in the null industry. This means that A’s stock grew significantly faster than CLPT’s over the last 12 months.
CLPT's P/E Growth Rating (14) in the null industry is in the same range as A (37) in the Biotechnology industry. This means that CLPT’s stock grew similarly to A’s over the last 12 months.
| A | CLPT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 66% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 67% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 64% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 62% | 2 days ago 85% |
| Advances ODDS (%) | 2 days ago 62% | 3 days ago 80% |
| Declines ODDS (%) | 4 days ago 63% | 9 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 69% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while CLPT’s FA Score has 2 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- CLPT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while CLPT’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 5 bearish.
- CLPT’s TA Score: 4 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а +2.16% price change this week, while CLPT (@Medical/Nursing Services) price change was +0.11% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.58%. For the same industry, the average monthly price growth was -10.79%, and the average quarterly price growth was -10.51%.
Reported Earning Dates
A is expected to report earnings on Nov 23, 2026.
CLPT is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.58% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
CLPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | -2.12% | ||
| ICUI - CLPT | 57% Loosely correlated | -0.15% | ||
| ISRG - CLPT | 46% Loosely correlated | -2.26% | ||
| A - CLPT | 45% Loosely correlated | +2.74% | ||
| NVST - CLPT | 45% Loosely correlated | +0.96% | ||
| SMTI - CLPT | 43% Loosely correlated | -1.12% | ||
More | ||||